Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefotaxime aminoglycoside interactions.

M A Pierce, A M Elliott, C G Cobbs

    Chemotherapy
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Cefotaxime combined with aminoglycosides like amikacin demonstrated synergistic killing of Enterobacteriaceae in vitro. This combination therapy shows promise for treating resistant bacterial infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Is birth weight associated with blood pressure among African children and adolescents? A systematic review.

    Journal of developmental origins of health and disease·2018
    Same author

    Characterization of plastic and boron carbide additive manufactured neutron collimators.

    The Review of scientific instruments·2018
    Same author

    Schistosoma mansoni-specific immune responses and allergy in Uganda.

    Parasite immunology·2017
    Same author

    Heart-hand syndrome IV: a second family with LMNA-related cardiomyopathy and brachydactyly.

    Clinical genetics·2016
    Same author

    Human eosinophils modulate peripheral blood mononuclear cell response to Schistosoma mansoni adult worm antigen in vitro.

    Parasite immunology·2016
    Same author

    Helminths are positively associated with atopy and wheeze in Ugandan fishing communities: results from a cross-sectional survey.

    Allergy·2016
    Same journal

    Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy.

    Chemotherapy·2026
    Same journal

    Pseudoprogression of a head and neck cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy: a case report and review of the literature.

    Chemotherapy·2026
    Same journal

    Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series.

    Chemotherapy·2026
    Same journal

    Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis.

    Chemotherapy·2026
    Same journal

    Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

    Chemotherapy·2026
    Same journal

    Expression of Concern.

    Chemotherapy·2026
    See all related articles

    Area of Science:

    • Microbiology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Enterobacteriaceae are significant human pathogens.
    • Antibiotic resistance necessitates novel therapeutic strategies.
    • Aminoglycosides and cefotaxime are key antimicrobial agents.

    Purpose of the Study:

    • To evaluate the in vitro activity of cefotaxime and aminoglycosides (gentamicin, tobramycin, amikacin) individually and in combination.
    • To determine synergistic bactericidal effects against Enterobacteriaceae.
    • To assess the stability of aminoglycoside concentrations when combined with cefotaxime.

    Main Methods:

    • Determination of minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs).
    • In vitro testing of cefotaxime, gentamicin, tobramycin, amikacin, and their combinations against 200 Enterobacteriaceae strains.

    Related Experiment Videos

  • Evaluation of synergistic killing in 95 strains and assessment of aminoglycoside stability with cefotaxime.

    • Main Results:

    • High susceptibility rates were observed for cefotaxime (91%), gentamicin (93.5%), and amikacin (89.5%).
    • Cefotaxime and amikacin exhibited the highest synergistic killing (78%), followed by cefotaxime and tobramycin (71%), and cefotaxime and gentamicin (64%).
    • Synergistic killing was demonstrated even in strains resistant to both agents, with stable aminoglycoside concentrations.

    Conclusions:

    • Combination therapy of cefotaxime with aminoglycosides, particularly amikacin, shows significant synergistic bactericidal activity against Enterobacteriaceae.
    • This combination is effective even against strains with dual resistance, suggesting clinical utility.
    • The stability of aminoglycosides in combination with cefotaxime supports their co-administration.